Can you really trust these Footsie big yielders to pay out?

Royston Wild discusses the payout prospects of three FTSE 100 dividend stocks.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Dividends are important and the appeal of some stocks relies on them. But sales difficulties across the entire business makes Centrica (LSE: CNA) a dicey pick for spectacular dividends, in my opinion.

The FTSE 100 (INDEXFTSE: UKX) energy play has cut the payout twice in the past two years as earnings have tanked. But the City expects payouts to turn higher again in 2016, even though a third successive dip is predicted. Last year’s reward of 12p per share is anticipated to rise to 12.3p, yielding a smashing 5.2%.

But the forecast 10% bottom-line dip leaves the dividend covered just 1.3 times by earnings, some way short of the safety benchmark of two times. And Centrica’s balance sheet can hardly be considered robust enough to support gargantuan dividends — net debt rang in at an eye-watering £3.8bn as of June.

Meanwhile, the revenues slump at Centrica show no sign of ending either. The firm saw accounts at British Gas slump a further 3% during January-March as competitive pressures increased. And abundant supply in the oil market threatens to keep crude values under the cosh too.

A sour dividend outlook

A patchy sales outlook at Sainsbury’s (LSE: SBRY) should also concern income chasers, in my opinion.

Like Centrica, the groceries goliath is being whacked by rising competition, particularly as shoppers flock in earnest to Aldi and Lidl. Indeed, latest Kantar Worldpanel data showed sales at Sainsbury’s eroded 0.6% during the 12 weeks to 14 August. By comparison, sales at Aldi and Lidl exploded 10.4% and 12.2% respectively.

And Sainsbury’s is likely to remain on a path of earnings-sapping price-cutting to stop the rot, a worrying omen for future dividends. The recent takeover of Argos will of course require massive investment too, as takings at the catalogue specialist are also spinning lower.

The number crunchers expect another dividend reduction at Sainsbury’s in the period to March 2017, to 10.3p per share from 12.1p last year, although this still yields a tempting 4.2%.

But while dividend coverage stands at a robust two times, due to a predicted 10% earnings fall, net debt of £1.83bn as of March — allied with the likelihood of prolonged sales pressures — makes me think that a much-bigger dividend cut could be on the cards.

Medical might

I have no fear that pharmaceuticals colossus AstraZeneca (LSE: AZN) is about to disappoint dividend hunters, however.

The City expects the Cambridge business to keep the dividend locked on hold at 280 US cents per share through to the end of next year. This results in a market-beating yield of 4.4%.

Expectations of further earnings weakness should naturally alarm dividend chasers, of course. The impact of patent expirations, and AstraZeneca’s delayed attempts to address this, is anticipated to result in modest single-digit earnings declines through to the close of 2017. And dividend cover comes in at around 1.5 times for this period too.

Still, I’m confident AstraZeneca’s pumped-up product pipeline should give it the confidence to ride out the current earnings storm and meet current forecasts. The successful launch of Tagrisso helped power sales at its new oncology unit to $251m during the first half, for example. And I believe AstraZeneca has plenty more rabbits to pull out of the hat in the months and years to come.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Royston Wild has no position in any shares mentioned. The Motley Fool UK has recommended AstraZeneca and Centrica. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

3 super-safe dividend shares I’d buy to target a £1,380 passive income!

Looking to maximise your chances of making a large passive income? These FTSE 100 and FTSE 250 dividend shares might…

Read more »

Investing Articles

I’ve just made a huge decision about my Scottish Mortgage shares!

Harvey Jones has done pretty well after buying Scottish Mortgage shares a year ago but the closer he examines the…

Read more »

Investing Articles

These top passive income stocks all go ex-dividend in October!

Paul Summers has been running the rule on some brilliant passive income stocks, all of which have ex-dividend deadlines coming…

Read more »

Warren Buffett at a Berkshire Hathaway AGM
Investing For Beginners

2 Warren Buffett-type stocks in the UK’s FTSE 100 index worth a look today

Warren Buffett likes to invest in high-quality companies. He also likes to buy when valuations are attractive and he can…

Read more »

artificial intelligence investing algorithms
Growth Shares

The next industrial revolution has begun. Here are 3 growth stocks at its heart

Edward Sheldon believes these three growth stocks will do well as the AI industry grows and the world becomes more…

Read more »

Investing Articles

Given the current economic climate, is there value to be found in UK penny stocks?

Our writer evaluates the prospects of two promising penny stocks on the London Stock Exchange. They each have a compelling…

Read more »

Investing Articles

With yields at 9%+, I expect even more from these FTSE 100 dividend stocks

I'd thought FTSE 100 yields might be declining by now, as the stock market starts to gain. Can these big…

Read more »

A young black man makes the symbol of a peace sign with two fingers
Investing Articles

2 risky shares for investors to consider buying

It’s important to consider what could go wrong when working out which shares to buy. But sometimes the potential rewards…

Read more »